American Association of Individual Investors2d
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Moderna, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Head and Neck Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...
Dispute Over Covid Vaccines Casts Doubt On Clover Bio Recovery
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...
GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
Shingles vaccine tied to a 20% lower risk of dementia among older people
The findings add to a growing body of evidence that the shingles vaccine may help keep dementia at bay – but researchers ...
Medscape3d
The Challenges of Chronic Cough
The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...
Verywell Health4d
A New FDA-Approved Antibiotic May Help Women With Recurring UTIs
If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
Exclusive-Pharma industry lobbies Trump for phased tariffs, sources say
LONDON/NEW YORK (Reuters) -Drugmakers are lobbying U.S. President Donald Trump to phase in tariffs on imported pharmaceutical ...
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
American Association of Individual Investors10d
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 10.08%
Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...